Low-dose Cytosine arabinoside; disease free survival and overall survival in the elderly patients with Acute Myeloid Leukemia
Abstract
Objectives: The median age of the patients with acute myeloid leukemia (AML) is 65 years. Studies have revealed that the prognosis of the elderly patients (over 60 years) is not satisfying. The aim of this study was to evaluate the survival of AML patients being treated with Low-dose Cytosine arabinoside.
Methodology: In this cross-sectional study, 20 AML patients treated with Low-dose Cytosine arabinoside. Disease free survival and overall five-year survival ratios were identified.
Results: In this study there were 11 males (55%) and nine female (45%) with a mean age of 63.3± 18.4 years. The median of disease free survival was 12.4 months and five-year survival was 1.7 years.
Conclusion: Apparently disease-free survival and overall five-year survival in the AML patients being treated with Low-dose Cytosine arabinoside are similar to that of cases being treated with intense chemotherapy regimens.
Methodology: In this cross-sectional study, 20 AML patients treated with Low-dose Cytosine arabinoside. Disease free survival and overall five-year survival ratios were identified.
Results: In this study there were 11 males (55%) and nine female (45%) with a mean age of 63.3± 18.4 years. The median of disease free survival was 12.4 months and five-year survival was 1.7 years.
Conclusion: Apparently disease-free survival and overall five-year survival in the AML patients being treated with Low-dose Cytosine arabinoside are similar to that of cases being treated with intense chemotherapy regimens.
Refbacks
- There are currently no refbacks.
